Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep 30;2015(9):CD011603.
doi: 10.1002/14651858.CD011603.pub2.

Buprenorphine for neuropathic pain in adults

Philip J Wiffen  1 , Sheena Derry, R Andrew Moore, Cathy Stannard, Dominic Aldington, Peter Cole, Roger Knaggs
Affiliations

Buprenorphine for neuropathic pain in adults

Philip J Wiffen et al. Cochrane Database Syst Rev. .

Abstract

Background: Opioid drugs, including buprenorphine, are commonly used to treat neuropathic pain, and are considered effective by some professionals. Most reviews have examined all opioids together. This review sought evidence specifically for buprenorphine, at any dose, and by any route of administration. Other opioids are considered in separate reviews.

Objectives: To assess the analgesic efficacy of buprenorphine for chronic neuropathic pain in adults, and the adverse events associated with its use in clinical trials.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from inception to 11 June 2015, together with reference lists of retrieved papers and reviews, and two online study registries.

Selection criteria: We included randomised, double-blind studies of two weeks' duration or longer, comparing any oral dose or formulation of buprenorphine with placebo or another active treatment in chronic neuropathic pain.

Data collection and analysis: Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality. We did not carry out any pooled analyses.

Main results: Searches identified 10 published studies, and one study with results in ClinicalTrials.gov. None of these 11 studies satisfied our inclusion criteria, and so we included no studies in the review.

Authors' conclusions: There was insufficient evidence to support or refute the suggestion that buprenorphine has any efficacy in any neuropathic pain condition.

PubMed Disclaimer

Conflict of interest statement

PW has no conflicts relating to this review or any similar product.

SD has no conflicts relating to this review or any similar product.

RAM has no conflicts relating to this review or any similar product.

CS has no conflicts relating to this review or any similar product.

DA has no conflicts relating to this review or any similar product.

PC has no conflicts relating to this review or any similar product.

RK has no conflicts relating to this review or any similar product.

We are funded by the NIHR for work on a series of reviews informing the unmet need of chronic pain and providing the evidence for treatments of pain.

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD011603

References

References to studies excluded from this review

Benedetti 1998 {published data only}
    1. Benedetti F, Vighetti S, Amanzio M, Casadio C, Oliaro A, Bergamasco B, et al. Dose‐response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain 1998;74(2‐3):205‐11. [DOI: 10.1016/S0304-3959(97)00172-3] - DOI - PubMed
Böhme 2003 {published data only}
    1. Böhme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS) in the treatment of patients with chronic pain. A randomised, double‐blind, placebo‐controlled study. Pain Clinic 2003;15:193‐202. [DOI: 10.1163/156856903321579334] - DOI
Canneti 2013 {published data only}
    1. Canneti A, Luzi M, Marco P, Cannata F, Pasqualitto F, Spinoglio A, et al. Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients. Minerva Anestesiologica 2013;79:871‐83. [PUBMED: 23558760] - PubMed
Kress 2009 {published data only}
    1. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. European Journal of Pain 2009;13(3):219‐30. [DOI: 10.1016/j.ejpain.2008.04.011] - DOI - PubMed
Landau 2007 {published data only}
    1. Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR. Buprenorphine transdermal delivery system in adults with persistent noncancer‐related pain syndromes who require opioid therapy: a multicenter, 5‐week run‐in and randomized, double‐blind maintenance‐of‐analgesia study. Clinical Therapeutics 2007;29(10):2179‐93. [DOI: 10.1016/j.clinthera.2007.10.010] - DOI - PubMed
NCT00312195 {published data only}
    1. Anon. Safety and efficacy of buprenorphine transdermal system (BTDS) in subjects with chronic nonmalignant pain, 2012. clinicaltrials.gov/ct2/show/NCT00312195 (accessed 11 June 2015).
Penza 2008 {published data only}
    1. Penza P, Campanella A, Martini A, Melli G, Lombardi R, Camozzi F, et al. Short‐ and intermediate‐term efficacy of buprenorphine TDS in chronic painful neuropathies. Journal of the Peripheral Nervous System 2008;13(4):283‐8. [DOI: 10.1111/j.1529-8027.2008.00194.x] - DOI - PubMed
Rodriguez‐Lopez 2004 {published data only}
    1. Rodriguez‐Lopez MJ, The Opioid Study Group of the Spanish Pain Society. Transdermal buprenorphine in the management of neuropathic pain. Revista de la Sociedad Española del Dolor 2004;11(Suppl V):11‐21.
Sittl 2003 {published data only}
    1. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double‐blind, placebo‐controlled trial. Clinical Therapeutics 2003;25(1):150‐68. [DOI: 10.1016/S0149-2918(03)90019-1] - DOI - PubMed
Sittl 2005 {published data only}
    1. Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Reviews in Neurotherapeutics 2005;5(3):315‐23. [DOI: 10.1586/14737175.5.3.315] - DOI - PubMed
Sorge 2004 {published data only}
    1. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics 2004;26(11):1808‐20. [10.10016/j clinthera,2004. 11008] - PubMed

Additional references

Bach 1991
    1. Bach V, Kamp‐Jensen M, Jensen NH, Eriksen J. Buprenorphine and sustained release morphine ‐ effect and side‐effects in chronic use. Pain Clinic 1991;4:87‐93.
Baron 2012
    1. Baron R, Wasner G, Binder A. Chronic pain: genes, plasticity, and phenotypes. Lancet Neurology 2012;11(1):19‐21. [DOI: 10.1016/S1474-4422(11)70281-2] - DOI - PubMed
Bouhassira 2008
    1. Bouhassira D, Lantéri‐Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380‐7. [DOI: 10.1016/j.pain.2007.08.013] - DOI - PubMed
Budd 2004
    1. Budd K, Shipton E. Acute pain and the immune system and opioimmunosuppression. Acute Pain 2004;6:123‐35.
Bullingham 1981
    1. Bullingham RES, McQuay HJ, Dwyer D, Allen MC, Moore RA. Sublingual buprenorphine used post‐operatively: clinical observations and preliminary pharmacokinetic analysis. British Journal of Clinical Pharmacology 1981;12:117‐22. [PUBMED: 7306425 ] - PMC - PubMed
Bullingham 1983
    1. Bullingham RES, McQuay HJ, Moore RA. Clinical pharmacokinetics of narcotic agonist‐antagonist drugs. Clinical Pharmacology 1983;8:332‐43. [PUBMED: 6352139] - PubMed
Bullingham 1984
    1. Bullingham RE, Moore RA, Symonds HW, Allen MC, Baldwin D, McQuay HJ. A novel form of dependency of hepatic extraction ratio of opioids in vivo upon the portal vein concentration of drug: comparison of morphine, diamorphine, fentanyl, methadone and buprenorphine in the chronically cannulated cow. Life Sciences 1984;34(21):2047‐56. [PUBMED: 6727551] - PubMed
Calvo 2012
    1. Calvo M, Dawes JM, Bennett DL. The role of the immune system in the generation of neuropathic pain. Lancet Neurology 2012;11(7):629‐42. [DOI: 10.1016/S1474-4422(12)70134-5] - DOI - PubMed
Dahan 2005
    1. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. British Journal of Anaesthesia 2005;94(6):825‐34. [DOI: 10.1093/bja/aei145] - DOI - PubMed
Dahan 2006
    1. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. British Journal of Anaesthesia 2006;96(5):627‐32. [DOI: 10.1093/bja/ael051] - DOI - PubMed
Demant 2014
    1. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain 2014;155(11):2263‐73. [DOI: 10.1016/j.pain.2014.08.014] - DOI - PubMed
Derry 2012
    1. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111] - DOI - PMC - PubMed
Derry 2013
    1. Derry S, Sven‐Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3] - DOI - PubMed
Derry 2014
    1. Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010958.pub2] - DOI - PMC - PubMed
Dworkin 2008
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] - DOI - PubMed
Elkader 2005
    1. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clinical Pharmacokinetics 2005;44(7):661‐80. [DOI: 10.2165/00003088-200544070-00001] - DOI - PubMed
Filitz 2006
    1. Filitz J, Griessinger N, Sittl R, Likar R, Schüttler J, Koppert W. Effect of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. European Journal of Pain 2006;10(8):743‐8. [DOI: 10.1016/j.ejpain.2005.12.001] - DOI - PubMed
Finnerup 2013
    1. Finnerup NB, Scholz J, Attal N, Baron R, Haanpää M, Hansson P, et al. Neuropathic pain needs systematic classification. European Journal of Pain 2013;17(7):953‐6. [DOI: 10.1002/j.1532-2149.2012.00282.x] - DOI - PubMed
Finnerup 2015
    1. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta‐analysis. Lancet Neurology 2015;14(2):162‐73. [DOI: 10.1016/S1474-4422(14)70251-0] - DOI - PMC - PubMed
Foster 2013
    1. Foster B, Twycross R, Mihalyo M, Wilcock A. Buprenorphine therapeutic reviews. Journal of Pain and Symptom Management 2013;45(5):939‐49. [DOI: 10.1016/j.jpainsymman.2013.03.001] - DOI - PubMed
Franklin 2014
    1. Franklin GM, American Academy of Neurology. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology 2014;83(14):1277‐84. [DOI: 10.1212/WNL.0000000000000839] - DOI - PubMed
Gal 1989
    1. Gal TJ. Naloxone reversal of buprenorphine‐induced respiratory depression. Clinical Pharmacology and Therapeutics 1989;45(1):6‐71. [PUBMED: 2491980] - PubMed
Gaskell 2014
    1. Gaskell H, Moore RA, Derry, S, Stannard C. Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD010692.pub2] - DOI - PubMed
Gustorff 2008
    1. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self‐reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132‐6. [DOI: 10.1111/j.1399-6576.2007.01486.x] - DOI - PubMed
Hakl 2012
    1. Hakl M. Transdermal buprenorphine in clinical practice: a multicenter, postmarketing study in the Czech Republic, with a focus on neuropathic pain components. Pain Management 2012;2(2):169. [DOI: 10.2217/pmt.11.92] - DOI - PubMed
Hall 2008
    1. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002‐2005. BMC Family Practice 2008;9:26. [DOI: 10.1186/1471-2296-9-26] - DOI - PMC - PubMed
Hall 2013
    1. Hall GC, Morant SV, Carroll D, Gabriel ZL, McQuay HJ. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Family Practice 2013;14:28. [DOI: 10.1186/1471-2296-14-28] - DOI - PMC - PubMed
Hand 1990
    1. Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. British Journal of Anaesthesia 1990;64(3):276‐82. - PubMed
Helfert 2015
    1. Helfert SM, Reimer M, Höper J, Baron R. Individualized pharmacological treatment of neuropathic pain. Clinical Pharmacology and Therapeutics 2015;97(2):135‐42. [DOI: 10.1002/cpt.19] - DOI - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hoffman 2010
    1. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?. Pain 2010;149(2):194‐201. [DOI: 10.1016/j.pain.2009.09.017] - DOI - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. [DOI: 10.1016/0197-2456(95)00134-4] - DOI - PubMed
Jensen 2011
    1. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011; Vol. 152, issue 10:2204‐5. [DOI: 10.1016/j.pain.2011.06.017] - DOI - PubMed
Kalso 2013
    1. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339. [DOI: 10.1136/bmj.f7339] - DOI - PubMed
Katusic 1991
    1. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945‐1984. Neuroepidemiology 1991;10:276‐81. [DOI: 10.1159/000110284] - DOI - PubMed
Koopman 2009
    1. Koopman JS, Dieleman JP, Huygen FJ, Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1‐3):122‐7. [DOI: 10.1016/j.pain.2009.08.023] - DOI - PubMed
Kusnik 2008
    1. Kusnik S, Likar R, Sittl R. Transdermal buprenorphine in chronic pain: indications and clinical experience. Expert Review of Clinical Pharmacology. 2008;1(6):729‐36. [DOI: 10.1586/17512433.1.6.729] - DOI - PubMed
L'Abbé 1987
    1. L'Abbé KA, Detsky AS, O'Rourke K. Meta‐analysis in clinical research. Annals of Internal Medicine 1987;107:224‐33. - PubMed
Lange 2010
    1. Lange B, Kuperwasser B, Okamoto A, Steup A, Häufel T, Ashworth J, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Advances in Therapy 2010;27(6):381‐99. [DOI: 10.1007/s12325-010-0036-3] - DOI - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine 2009;151(4):W65‐94. [DOI: 10.7326/0003-4819-151-4-200908180-00136] - DOI - PubMed
Licina 2013
    1. Licina L, Hamsher C, Lautenschager K, Dhanjal S, Williams N, Spevak C. Buprenorphine/naloxone therapy for opioid refractory neuropathic pain following traumatic amputation: a case series. Military Medicine 2013;178(7):e858‐61. [DOI: 10.7205/MILMED-D-12-00310] - DOI - PubMed
Lunn 2014
    1. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3] - DOI - PMC - PubMed
McNicol 2013
    1. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD006146.pub2] - DOI - PMC - PubMed
McQuay 1998
    1. McQuay H, Moore R. An Evidence‐Based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0‐19‐263048‐2]
McQuay 2007
    1. McQuay HJ, Smith LA, Moore RA. Chronic pain. In: Stevens A, Raftery J, Mant J, Simpson S editor(s). Health Care Needs Assessment, 3rd Series. Oxford: Radcliffe Publishing, 2007. [ISBN: 978‐1‐84619‐063‐6]
Moore 1998
    1. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209‐16. [DOI: 10.1016/S0304-3959(98)00140-7] - DOI - PubMed
Moore 2008
    1. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5]
Moore 2009
    1. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] - DOI - PMC - PubMed
Moore 2010a
    1. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] - DOI - PubMed
Moore 2010b
    1. Moore RA, Straube S, Derry S, McQuay HJ. Chronic low back pain analgesic studies ‐ a methodological minefield. Pain 2010;149(3):431‐4. [DOI: 10.1016/j.pain.2010.02.032] - DOI - PubMed
Moore 2010c
    1. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] - DOI - PubMed
Moore 2010d
    1. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers‐needed‐to‐treat analyses ‐ do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo‐controlled chronic low back pain trials. Pain 2010;151(3):592‐7. [DOI: 10.1016/j.pain.2010.07.013] - DOI - PubMed
Moore 2010e
    1. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374‐9. [DOI: 10.1136/ard.2009.107805] - DOI - PMC - PubMed
Moore 2011a
    1. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta‐analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982‐9. [DOI: 10.1016/j.pain.2010.11.030] - DOI - PubMed
Moore 2011b
    1. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post‐operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427‐32. [DOI: 10.1097/EJA.0b013e328343c569] - DOI - PubMed
Moore 2012a
    1. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2] - DOI - PubMed
Moore 2012b
    1. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004] - DOI - PubMed
Moore 2013a
    1. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690] - DOI - PubMed
Moore 2013b
    1. Moore RA, Straube S, Aldington D. Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400‐12. [DOI: 10.1111/anae.12148] - DOI - PubMed
Moore 2014a
    1. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79‐94. [DOI: 10.1111/papr.12050] - DOI - PubMed
Moore 2014b
    1. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3] - DOI - PMC - PubMed
Moore 2014c
    1. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions ‐ individual patient data responder analysis. European Journal of Pain 2014;18(1):67‐75. [DOI: 10.1002/j.1532-2149.2013.00341.x] - DOI - PMC - PubMed
NICE 2012
    1. National Institute for Health and Care Excellence (NICE). Opioids in palliative care, 2012. www.nice.org.uk/guidance/cg140 (accessed 11 June 2015).
NICE 2013
    1. National Institute for Health and Care Excellence (NICE). Neuropathic pain ‐ pharmacological management: the pharmacological management of neuropathic pain in adults in non‐specialist settings, 2013. www.nice.org.uk/guidance/cg173 (accessed 11 June 2015). - PubMed
O'Brien 2010
    1. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient‐centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6‐15. [DOI: 10.1111/j.1526-4637.2009.00685] - DOI - PubMed
Pace 2007
    1. Pace MC, Passavanti MB, Grella E, Mazzariello L, Maisto M, Barbarisi M, et al. Buprenorphine in long‐term control of chronic pain in cancer patients. Frontiers in Bioscience 2007;12:1291‐9. [PUBMED: 17127381] - PubMed
PaPaS 2012
    1. Cochrane Pain, Palliative and Supportive Care Group (PaPaS) author and referee guidance. papas.cochrane.org/papas‐documents (accessed 11 June 2015).
Pergolizzi 2010
    1. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Practice 2010;10(5):428‐60. [DOI: 10.1111/j.1533-2500.2010.00378.x] - DOI - PubMed
Rappaport 1994
    1. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self‐sustaining discharge in the trigeminal ganglion. Pain 1994;56:127‐38. [DOI: 10.1016/0304-3959(94)90086-8] - DOI - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sacerdote 2000
    1. Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesthesia & Analgesia 2000;90(6):1411‐4. [DOI: 10.1097/00000539-200006000-00028] - DOI - PubMed
Sacerdote 2008
    1. Sacerdote P, Franchi S, Gerra G, Leccese V, Panerai AE, Somaini L. Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function. Brain, Behavior, and Immunity 2008;22(4):606‐13. [DOI: 10.1016/j.bbi.2007.12.013] - DOI - PubMed
Staritz 1986
    1. Staritz M, Poralla T, Manns M, Meyer Zum Büschenfelde KH. Effect of modern analgesic drugs (tramadol, pentazocine and buprenorphine) on the bile duct sphincter in man. Gut 1986;27(5):567‐9. [PUBMED: 3699566] - PMC - PubMed
Straube 2008
    1. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266‐75. [DOI: 10.1111/j.1365-2125.2008.03200] - DOI - PMC - PubMed
Straube 2010
    1. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia ‐ responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150] - DOI - PMC - PubMed
Sultan 2008
    1. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-9] - DOI - PMC - PubMed
Torrance 2006
    1. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain 2006;7(4):281‐9. [DOI: 10.1016/j.jpain.2005.11.008] - DOI - PubMed
Treede 2008
    1. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630‐5. [DOI: 10.1212/01.wnl.0000282763.29778.59] - DOI - PubMed
van Hecke 2014
    1. Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014;155(4):654‐62. [DOI: 10.1016/j.pain.2013.11.013] - DOI - PubMed
von Hehn 2012
    1. Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012;73(4):638‐52. [DOI: 10.1016/j.neuron.2012.02.008] - DOI - PMC - PubMed
Vos 2012
    1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163‐96. [DOI: 10.1016/S0140-6736(12)61729-2] - DOI - PMC - PubMed
Walsh 2003
    1. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug and Alcohol Dependence 2003;70(2 Suppl):S13‐27. [DOI: 10.1016/S0376-8716(03)00056-5] - DOI - PubMed
Weiner 2012
    1. Weiner M, Sarantopoulos C, Gordon E. Transdermal buprenorphine controls central neuropathic pain. Journal of Opioid Management 2012;8(6):414‐5. [DOI: 10.5055/jom.2012.0141] - DOI - PubMed
WHO 1996
    1. World Health Organization (WHO). Cancer pain relief, 1996. whqlibdoc.who.int/publications/9241544821.pdf (accessed 11 June 2015). [ISBN: 92 4 154482 1]
Wiffen 2013
    1. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2] - DOI - PMC - PubMed

Publication types

LinkOut - more resources